āagmanLoginNot investment advice. Data and computed figures, for information only.
Entero Healthcare Solutions Ltd
₹1,581.10
−₹10.60 (−0.67%)
NSE · 15 Oct 2026, close
Market Cap
₹7,295 Cr
CMP
₹1,581.10
52-wk High / Low
₹1,920 / 944
P/E
56.5
P/B
4.3
Book Value
₹388.0
Div Yield
0.00%
ROCE
10.0%
ROE
6.9%
Face Value
₹10
D/E
0.40
Price+40.8% over 1Y
āagman read
Computed by āagmanPiotroski F-Score
5
/ 9
5 of 9 F-score tests passed
Graham Number
₹480
√(22.5 × EPS × book value per share)
ROIC
7.7%
vs 7.6% sector median
Cash flow to profit
0.66
CFO / PAT
Above 1.0 = operating cash flow exceeded reported profit
Margin change
+144
bps OPM YoY
Operating margin vs the same quarter last year
Sustainable growth
6.9%
ROE × earnings retention ratio
ROE stability
2.6
pp σ
Standard deviation of ROE across periods. Lower = more stable
Holder deltas
QoQ
pp
Prom −0.02FII +0.33DII −1.14
Latest quarter vs the previous one
Cash-accrual divergence
1.6%
of assets
Low = accruals track cash flow
Strengths
+Price trades above its 200-day moving average (1.2x)
Watch-outs
−Latest ROCE of 10% trails the sector median of 13%
Peer comparison
| Name | P/E | Mar Cap ₹ Cr | ROCE % | ROE % |
|---|
Quarterly results
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 899 | 996 | 993 | 1,034 | 1,097 | 1,301 | 1,359 | 1,339 | 1,404 | 1,571 | 1,707 | 1,910 | 1,940 |
| Expenses | 873 | 968 | 964 | 1,005 | 1,067 | 1,258 | 1,309 | 1,290 | 1,354 | 1,509 | 1,639 | 1,824 | 1,844 |
| Operating Profit | 26 | 29 | 29 | 29 | 30 | 42 | 50 | 49 | 50 | 62 | 68 | 86 | 97 |
| OPM % | 2.9% | 2.9% | 2.9% | 2.8% | 2.7% | 3.2% | 3.7% | 3.7% | 3.6% | 3.9% | 4.0% | 4.5% | 5.0% |
| Other Income | 1 | 2 | 2 | 9 | 13 | 11 | 8 | 7 | 6 | 5 | −4 | 4 | 3 |
| Interest | 14 | 18 | 16 | 17 | 10 | 11 | 10 | 10 | 11 | 12 | 14 | 17 | 21 |
| Depreciation | 6 | 6 | 6 | 7 | 7 | 7 | 8 | 8 | 9 | 10 | 10 | 15 | 12 |
| Profit before tax | 7 | 7 | 8 | 14 | 27 | 35 | 39 | 37 | 36 | 45 | 40 | 58 | 67 |
| Net Profit | 6 | 5 | 7 | 21 | 21 | 26 | 29 | 31 | 30 | 37 | 34 | 45 | 52 |
| EPS (₹) | 15.18 | 3.19 | 4.22 | 4.82 | 4.62 | 5.43 | 5.85 | 5.90 | 6.39 | 7.26 | 6.35 | 6.44 | 8.77 |
Profit & Loss
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,350 | 1,773 | 2,522 | 3,300 | 3,922 | 5,096 | 6,591 | 7,128 |
| Expenses | 1,326 | 1,758 | 2,498 | 3,236 | 3,810 | 4,924 | 6,325 | 6,815 |
| Operating Profit | 23 | 15 | 24 | 64 | 112 | 172 | 266 | 313 |
| OPM % | 1.7% | 0.8% | 1.0% | 1.9% | 2.9% | 3.4% | 4.0% | 4.4% |
| Other Income | 5 | 11 | 4 | 6 | 14 | 39 | 11 | 8 |
| Interest | 13 | 20 | 29 | 49 | 66 | 42 | 54 | 64 |
| Depreciation | 12 | 16 | 20 | 24 | 25 | 31 | 43 | 47 |
| Profit before tax | 4 | −11 | −20 | −4 | 36 | 139 | 179 | 210 |
| Net Profit | 1 | −15 | −29 | −11 | 40 | 107 | 146 | 168 |
| EPS (₹) | 93.81 | −1,550.90 | −77.71 | −28.12 | 8.99 | 21.79 | 26.44 | 28.82 |
Balance Sheet
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0 | 0 | 4 | 4 | 43 | 44 | 44 | — |
| Reserves | −16 | −32 | −62 | −73 | 1,595 | 1,681 | 1,645 | — |
| Borrowings | 603 | 720 | 974 | 1,101 | 338 | 385 | 677 | — |
| Other Liabilities | 162 | 147 | 210 | 275 | 369 | 593 | 1,234 | — |
| Total Liabilities | 749 | 836 | 1,125 | 1,308 | 2,345 | 2,703 | 3,600 | — |
| Fixed Assets | 186 | 189 | 262 | 268 | 289 | 559 | 958 | — |
| CWIP | 2 | 2 | 1 | 0 | 0 | 0 | 2 | — |
| Investments | 0 | 0 | 0 | 0 | 0 | 58 | 130 | — |
| Other Assets | 560 | 645 | 863 | 1,040 | 2,056 | 2,085 | 2,510 | — |
| Total Assets | 749 | 836 | 1,125 | 1,308 | 2,345 | 2,703 | 3,600 | — |
Cash Flows
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | −37 | −69 | −35 | −45 | −37 | −77 | 96 |
| Cash from Investing Activity | −203 | −31 | −162 | −49 | −704 | 232 | −302 |
| Cash from Financing Activity | 217 | 89 | 211 | 73 | 863 | −74 | 124 |
| Net Cash Flow | −23 | −11 | 14 | −21 | 122 | 82 | −82 |
Ratios
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| ROCE % | — | 1.0 | 1.0 | 5.0 | 7.0 | 9.0 | 10.0 |
| ROE % | — | — | — | — | — | — | 6.9 |
| EPS (₹) | 93.81 | −1,550.90 | −77.71 | −28.12 | 8.99 | 21.79 | 26.44 |
| Book Value (₹) | — | — | — | — | — | — | 388.0 |
| Face Value (₹) | — | — | — | — | — | — | 10 |
| P/E | — | — | — | — | — | — | 56.5 |
| Div Yield % | — | — | — | — | — | — | 0.00 |
| NPM % | 0.1 | −0.8 | −1.1 | −0.3 | 1.0 | 2.1 | 2.2 |
| OPM % | 1.7 | 0.8 | 1.0 | 1.9 | 2.9 | 3.4 | 4.0 |
| D/E | — | — | — | — | 0.21 | 0.22 | 0.40 |
| P/B | — | — | — | — | — | — | 4.3 |
Growth
Compounded sales growth
5 years+30.0%
3 years+26.0%
TTM+32.0%
Compounded profit growth
5 years+57.0%
3 years+130.0%
TTM+26.0%
Stock price CAGR
Last year+49.0%
Return on equity
3 years6.0%
Last year7.0%
Documents
Announcements
Closure of Trading WindowAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDisclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011Entero Healthcare Solutions Limited Has informed About General UpdatesDisclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011Corporate actions
Fundamentals from a third-party compiler of exchange filings; prices from the exchanges. Not investment advice.© 2026 āagman